Skip to main content

Incyte to Present at Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:

  • Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT)



  • Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT)



  • Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:45 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.30
-1.85 (-0.74%)
AAPL  329.88
-3.13 (-0.94%)
AMD  604.24
-7.52 (-1.23%)
BAC  53.09
-1.34 (-2.45%)
GOOG  339.00
-1.74 (-0.51%)
META  723.37
-1.81 (-0.25%)
MSFT  516.88
+3.98 (0.78%)
NVDA  229.68
+1.30 (0.57%)
ORCL  136.12
-1.18 (-0.86%)
TSLA  355.10
+0.29 (0.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.